I think we need to know if the FDA are going to stamp
our drug as DMOAD. This is the key item we need addressed
before a value can be assigned to the asset. It appears this has been pushed back to Q1 2024.
Further, MPS 1 asset has answered one of the unknowns, we are safe and effective for BOTH nezyme replacement therapy and bone marrow transplant therapy subjects.
Also our MPS 6 asset (as Mozz points out) may obtain a commercial licence on the back of its study that is about to finalise in Brazil. The orphan indication, with potential fast track to market designation in Brazil, gives the company a price point for Zilosul, which we can point to in the various regulatory and commercial discussions that are upcoming.
I think we need to know if the FDA are going to stampour drug as...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.010(3.92%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.0¢ | $59.66K | 241.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78837 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 36290 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |